Skip to main content
SpringerLink
Log in

Should Sexual Desire and Arousal Disorders in Women Be Merged?

  • Letter to the Editor
  • Published:
Archives of Sexual Behavior Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  • American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: American Psychiatric Association.

  • Brotto, L. A. (2010). The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Archives of Sexual Behavior, 39, 221–239.

    Article  PubMed  Google Scholar 

  • Clayton, A. H., DeRogatis, L. R., Rosen, R., Pyke, R., Garcia, M., & Sand, M. (2010). Do clinical research data support sexual desire and arousal disorders as distinct diagnoses? Journal of Sexual Medicine, 7(Suppl. 3), 143–144.

    Google Scholar 

  • DeRogatis, L. R., Clayton, A. H., Rosen, R., Sand, M., Garcia, M., & Pyke, R. (2010a). Do multiple convergent measures of female sexual dysfunction support sexual desire and arousal disorders as distinct diagnoses? Journal of Sexual Medicine, 7(Suppl. 3), 142–143.

    Google Scholar 

  • DeRogatis, L. R., Laan, E., Brauer, M., van Lunsen, R. H. W., Jannini, E. A., Davis, S. R., et al. (2010b). Responses to the proposed DSM-V changes. Journal of Sexual Medicine, 7, 1998–2014.

    Article  PubMed  Google Scholar 

  • Jolly, E., Clayton, A. H., Thorp, J., Nappi, R., Kimura, T., & Pyke, R. (2009). Design of randomized controlled trials of flibanserin in premenopausal women with hypoactive sexual desire disorder. Journal of Sexual Medicine, 6(Suppl. 5), 465.

    Google Scholar 

  • Lewis-D’Agostino, D., Clayton, A. H., Wunderlich, G., Kimura, T., DeRogatis, L., & Goldstein, A. (2007). Validating the sexual interest and desire inventory-female (SIDI-F) in North American women. Obstetrics and Gynecology, 109(Suppl. 4), 23S.

    Google Scholar 

Download references

Acknowledgments

Editorial assistance for this Letter was provided by Wendy Morris, Fleishman-Hillard Group Ltd. (contracted by Boehringer Ingelheim). Dr. DeRogatis is a Consultant to Boehringer Ingelheim, Biosante, Inc., Faber-Kramer Pharmaceuticals, and Endoceutics, Inc. Dr. Clayton led the development and validation of the Changes in Sexual Functioning Questionnaire (CSFQ), Sexual Interest and Desire Inventory (SIDI-F), and the Decreased Sexual Desire Screener (DSDS). She was Chair of the Third International Consultation on Sexual Medicine Committee for Standards for Clinical Trials in Sexual Dysfunction in Women: Research Designs and Outcomes Assessment (2009). She has been the Principal Investigator for many studies of Hypoactive Sexual Desire Disorder (HSDD): GlaxoSmithKline Phase IV trial of bupropion, Boehringer Ingelheim Phase III trials of flibanserin in premenopausal women, and BioSante Phase III trials of libigel in postmenopausal women. She is a Consultant to Boehringer Ingelheim, TransTech Pharma, and New England Research Institutes regarding Female Sexual Dysfunction (FSD), and to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Labopharm, Pfizer, PGxHealth, sanofi-aventis, and Takeda about sexual effects of psychotropic medications. Dr. Clayton has been a speaker for CME programs on HSDD supported by Boehringer Ingelheim. She receives royalties from: “Satisfaction: Women, Sex, and the Quest for Intimacy” published by Ballantine Books/Random House, “Women’s Mental Health: A Comprehensive Textbook” published by Guilford Publications, and the CSFQ. Dr. Rosen is a Consultant to Boehringer Ingelheim, Endo Pharmaceuticals, Eli Lilly, and Johnson and Johnson. Dr. Sand is the Global Strategic Leader for the flibanserin clinical development program at Boehringer Ingelheim. Dr. Pyke has been the Team Member (for) Medicine for the flibanserin premenopausal HSDD clinical development project at Boehringer Ingelheim since 2003. He was involved in the management of protocol content, field conduct, and interpretation of results for two Phase 2 trials (over 400 patients evaluated), seven Phase 3 trials (over 6,000 patients evaluated), two trials of SSRI users (over 100 patients evaluated so far), and six non-treatment studies on validation of measures of FSD (over 1000 patients evaluated). In this role, he helped lead development and testing of an integrated set of diagnostic evaluations for FSD, including a 60-question structured clinical interview appropriate for DSM-IV-TR, checklists on DSM-IV-TR and AUAF consensus diagnostic criteria, an AUAF consensus contributory factors checklist, and a brief form for non-expert clinicians to diagnose HSDD; one or more of these forms have been used in diagnostic interviews conducted with over 10,000 women in North America and Europe.

Author information

Authors and Affiliations

  1. Center for Sexual Medicine at Sheppard Pratt, Johns Hopkins University School of Medicine, 6501 N. Charles St., Baltimore, MD, 21285-6815, USA

    Leonard R. DeRogatis

  2. Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, USA

    Anita H. Clayton

  3. New England Research Institutes, Watertown, MA, USA

    Raymond C. Rosen

  4. Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA

    Michael Sand & Robert E. Pyke

Authors
  1. Leonard R. DeRogatis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anita H. Clayton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raymond C. Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Sand
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert E. Pyke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonard R. DeRogatis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

DeRogatis, L.R., Clayton, A.H., Rosen, R.C. et al. Should Sexual Desire and Arousal Disorders in Women Be Merged?. Arch Sex Behav 40, 217–219 (2011). https://doi.org/10.1007/s10508-010-9677-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10508-010-9677-1

Keywords

Search

Navigation